These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 3450297)
1. Modification of the basic side chain in tamoxifen: effects on microsomal metabolism and in vitro biological activity. Foster AB; McCague R; Seago A; Leclercq G; Stoessel S; Roy F Anticancer Drug Des; 1986 Nov; 1(3):245-57. PubMed ID: 3450297 [TBL] [Abstract][Full Text] [Related]
2. Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts. Jarman M; Leung OT; Leclercq G; Devleeschouwer N; Stoessel S; Coombes RC; Skilton RA Anticancer Drug Des; 1986 Nov; 1(3):259-68. PubMed ID: 3450298 [TBL] [Abstract][Full Text] [Related]
3. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells. Kraft KS; Ruenitz PC; Bartlett MG J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents. Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397 [TBL] [Abstract][Full Text] [Related]
5. Species differences in metabolism of panomifene, an analogue of tamoxifen. Monostory K; Jemnitz K; Vereczkey L; Czira G Drug Metab Dispos; 1997 Dec; 25(12):1370-8. PubMed ID: 9394026 [TBL] [Abstract][Full Text] [Related]
6. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874 [TBL] [Abstract][Full Text] [Related]
7. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites. Watts CK; Sutherland RL Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893 [TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells. Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807 [TBL] [Abstract][Full Text] [Related]
9. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length. Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423 [TBL] [Abstract][Full Text] [Related]
10. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124 [TBL] [Abstract][Full Text] [Related]
11. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Mani C; Hodgson E; Kupfer D Drug Metab Dispos; 1993; 21(4):657-61. PubMed ID: 8104125 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Coezy E; Borgna JL; Rochefort H Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859 [TBL] [Abstract][Full Text] [Related]
13. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells. Miller MA; Lippman ME; Katzenellenbogen BS Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162 [TBL] [Abstract][Full Text] [Related]
14. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines. ter Haar E; Day BW Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221 [TBL] [Abstract][Full Text] [Related]
15. Species-specific pharmacology of antiestrogens: role of metabolism. Jordan VC; Robinson SP Fed Proc; 1987 Apr; 46(5):1870-4. PubMed ID: 3556610 [TBL] [Abstract][Full Text] [Related]
16. Metabolism of 1,1-dichloro-cis-diphenylcyclopropane by rat liver microsomes. Caputo O; Grosa G; Ceruti M; Rocco F; Biglino G Drug Metab Dispos; 1990; 18(5):771-8. PubMed ID: 1981735 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains. Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086 [TBL] [Abstract][Full Text] [Related]
19. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Wakeling AE; Slater SR Cancer Treat Rep; 1980; 64(6-7):741-4. PubMed ID: 7427959 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]